| [1] |
Tong X, Zhao F, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells[J]. Curr Opin Genet Dev, 2009, 19(1):32-37.
|
| [2] |
Ruiz-Perez MV, Sanchez-Jimenez F, Alonso FJ, et al. Glutamine, glucose and other fuels for cancer[J]. Curr Pharm Des, 2014, 20(15):2557-2579.
|
| [3] |
Matés JM, Segura JA, Martín-Rufián M, et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer[J]. Curr Mol Med, 2013, 13(4):514-534.
pmid: 22934847
|
| [4] |
Márquez J, Matés JM, Campos-Sandoval JA. Glutamina-ses[J]. Adv Neurobiol, 2016, 13:133-171.
pmid: 27885629
|
| [5] |
Martín-Rufián M, Tosina M, Campos-Sandoval JA, et al. Mammalian glutaminase Gls2 gene encodes two func-tional alternative transcripts by a surrogate promoter usage mechanism[J]. PloS One, 2012, 7(6):e38380.
|
| [6] |
Szeliga M, Bogacińska-Karaś M, RÓzycka A, et al. Silencing of GLS and overexpression of GLS2 genes coo-perate in decreasing the proliferation and viability of glioblastoma cells[J]. Tumor Biol, 2014, 35(3):1855-1862.
|
| [7] |
Aledo JC, GÓmez-Fabre PM, Olalla L, et al. Identification of two human glutaminase loci and tissue-specific expression of the two related genes[J]. Mamm Genome, 2000, 11(12):1107-1110.
pmid: 11130979
|
| [8] |
Majewska E, Márquez J, Albrecht J, et al. Transfection with GLS2 glutaminase (GAB) sensitizes human glioblastoma cell lines to oxidative stress by a common mechanism involving suppression of the PI3K/AKT pathway[J]. Cancers (Basel), 2019, 11(1). pii: E115.
|
| [9] |
Juan L, Cen Z, Meihua L, et al. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma[J]. Oncotarget, 2014, 5(9):2635-2647.
doi: 10.18632/oncotarget.1862
pmid: 24797434
|
| [10] |
Lukey MJ, Cluntun AA, Katt WP, et al. Liver-type glutaminase GLS2 Is a druggable metabolic node in luminal-subtype breast cancer[J]. Cell Rep, 2019, 29(1):76-88.
|
| [11] |
Márquez J, Matés JM, Alonso FJ, et al. Canceromics studies unravel tumor's glutamine addiction after metabolic reprogramming[M]// Mazurek S, Shoshan M. Tumor Cell Metabolism. Vienna:Springer, 2015:257-286.
|
| [12] |
DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer[J]. Oncogene, 2010, 29(3):313-324.
doi: 10.1038/onc.2009.358
pmid: 19881548
|
| [13] |
Stalnecker CA, Ulrich SM, Li Y, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells[J]. Proc Natl Acad Sci U S A, 2015, 112(2):394-399.
doi: 10.1073/pnas.1414056112
pmid: 25548170
|
| [14] |
Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?[J]. Cell Cycle, 2010, 9(19):3884-3886.
pmid: 20948290
|
| [15] |
Yuneva MO, Fan TW, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type[J]. Cell Metab, 2012, 15(2):157-170.
|
| [16] |
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy[J]. Nat Rev Cancer, 2016, 16(11):749.
doi: 10.1038/nrc.2016.114
pmid: 28704361
|
| [17] |
GTEx Consortium. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans[J]. Science, 2015, 348(6235):648-660.
|
| [18] |
Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species[J]. Proc Natl Acad Sci U S A, 2010, 107(16):7461-7466.
|
| [19] |
Xiao D, Ren P, Su H, et al. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2[J]. Oncotarget, 2015, 6(38):40655-40666.
|
| [20] |
Hu W, Zhang C, Wu R, et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function[J]. Proc Natl Acad Sci U S A, 2010, 107(16):7455-7460.
|
| [21] |
Yu D, Shi X, Meng G, et al. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma[J]. Oncotarget, 2015, 6(10):7619-7631.
|
| [22] |
Márquez J, de la Oliva AR, Matés JM, et al. Glutaminase: a multifaceted protein not only involved in generating glutamate[J]. Neurochem Int, 2006, 48(6):465-471.
|
| [23] |
Kuo TC, Chen CK, Hua KT, et al. Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells[J]. Cancer letters, 2016, 383(2):282-294.
|
| [24] |
Zhang C, Liu J, Zhao Y et al. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis[J]. Elife, 2016, 5:e10727.
|
| [25] |
Tania V, Francesco R, Paola T, et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation[J]. Cell Cycle, 2013, 12(22):3564-3573.
|
| [26] |
Szeliga M, Zgrzywa A, Obara-Michlewska M, et al. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents[J]. J Neurochem, 2012, 123(3):428-436.
doi: 10.1111/j.1471-4159.2012.07917.x
pmid: 22888977
|
| [27] |
Niu Y, Zhang J, Tong Y, et al. Physcion 8-O-beta-glucopyranoside induced ferroptosis via regulating miR-103a-3p/GLS2 axis in gastric cancer[J]. Life Sci, 2019, 237:116893.
|
| [28] |
Xiang L, Xie G, Liu C, et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation[J]. Biochim Biophys Acta, 2013, 1833(12):2996-3005.
|
| [29] |
Ramirez-Peña E, Arnold J, Shivakumar V, et al. The epithelial to mesenchymal transition promotes glutamine independence by suppressing GLS2 expression[J]. Cancers(Basel), 2019, 11(10).pii:E1610.
|
| [30] |
李妮. 缺氧诱导因子1α调控2型谷氨酰胺酶促进结肠癌耐药的机制及临床意义研究[D]. 重庆: 第三军医大学, 2016.
|
